BioNTech (NASDAQ:BNTX) CEO Sells 27,000 Shares of Company Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 27,000 shares of the company’s stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $92.31, for a total transaction of $2,492,370.00. Following the completion of the sale, the chief executive officer owned 36,209 shares in the company, valued at approximately $3,342,452.79. This trade represents a 42.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, October 9th, Ugur Sahin sold 36,209 shares of BioNTech stock. The stock was sold at an average price of $95.37, for a total value of $3,453,252.33.
• On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The stock was sold at an average price of $95.86, for a total value of $2,300,640.00.
• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total value of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The stock was sold at an average price of $97.23, for a total value of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The shares were sold at an average price of $97.46, for a total transaction of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total transaction of $2,982,000.00.

BioNTech Stock Up 5.3%

NASDAQ BNTX traded up $4.90 during mid-day trading on Friday, reaching $96.96. The stock had a trading volume of 1,288,649 shares, compared to its average volume of 1,088,842. The stock has a market cap of $24.52 billion, a PE ratio of -12.38 and a beta of 1.25. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The company has a fifty day moving average price of $99.04 and a 200 day moving average price of $95.16.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. During the same period in the previous year, the business posted ($1.60) EPS. The firm’s revenue for the quarter was down 59.5% on a year-over-year basis. On average, research analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC boosted its position in shares of BioNTech by 31.5% during the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after acquiring an additional 118 shares during the last quarter. Quintet Private Bank Europe S.A. increased its stake in BioNTech by 232.8% in the 3rd quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock worth $188,000 after acquiring an additional 1,341 shares during the last quarter. Engineers Gate Manager LP raised its holdings in shares of BioNTech by 17.3% during the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock worth $1,157,000 after acquiring an additional 1,833 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech during the 2nd quarter valued at approximately $39,000. Finally, Nykredit A S bought a new position in shares of BioNTech during the 2nd quarter valued at approximately $293,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BNTX. Canaccord Genuity Group reduced their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research report on Friday, October 2nd. Argus assumed coverage on shares of BioNTech in a research note on Thursday. They set a “hold” rating for the company. UBS Group restated a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. Finally, Berenberg Bank set a $140.00 price objective on BioNTech in a report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $125.69.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.